Published in final edited form as:

Bioorg Med Chem Lett. 2010 July 1; 20(13): 3848–3850. doi:10.1016/j.bmcl.2010.05.057.

Inhibition of ABCG2-Mediated Drug Efflux by Naphthopyrones from Marine Crinoids

Heidi R. Bokesch^{a,b}, Laura K. Cartner^{a,b}, Richard W. Fuller^a, Jennifer A. Wilson^a, Curtis J. Henrich^{a,b}, James A. Kelley^c, Kirk R. Gustafson^a, James B. McMahon^a, and Tawnya C. McKee^a

^aMolecular Targets Laboratory, NCI-Frederick, Frederick, MD, 21702, USA

^bSAIC-Frederick, Inc, NCI-Frederick, Frederick, MD, 21702, USA

^cChemical Biology Laboratory, NCI-Frederick, Frederick, MD, 21702, USA

Abstract

Five new naphthopyrones (**1-5**) along with the known compounds TMC-256A1, 5,8-dihydroxy-6-methoxy-2-propyl-4*H*-naphtho[2,3-*b*]pyran-4-one, TMC-256C1, comaparvin, 6-methoxy comaparvin, and 6-methoxycomarparvin 5-methyl ether (**7-11**) were isolated from crinoids of the family Comasteridae. All compounds were tested for their ability to inhibit the multidrug transporter ABCG2, which plays a role in drug resistance. Six of the seven angular naphthopyrones showed moderate activity with <60% inhibition of ABCG2 –mediated transport as compared to the positive control fumitremorgin C. None of the linear naphthopyrones inhibited ABCG2 –mediated efflux.

ABCG2 (BCRP/breast cancer resistance protein) is a multidrug transporter belonging to the ATP-binding cassette (ABC) superfamily of membrane proteins. It is one of several cellular transporters that are implicated in the multiple drug resistance (MDR) phenotype which is at least partially responsible for chemotherapeutic drug resistance. ABCG2 is expressed in the liver, small intestine, kidney, colon, brain endothelial cells, hematopoietic stem cells and placenta, which suggests a major role in limiting the bioavailability and penetration of xenobiotics, as well as protecting the blood-brain barrier.^{1,2} It is able to efflux a wide range of structurally and mechanistically diverse drugs from cells. Therefore developing inhibitors of ABCG2 potentially offers an opportunity to reverse drug-resistance, alter uptake of substrate drugs, improve oral bioavailability, and target stem cells. Many of the known inhibitors of ABCG2 are derived from natural products and the recent identification in our laboratory of a series of botryllamides,³ a new compound class of ABCG2 inhibitors, prompted us to screen for additional inhibitors of ABCG2.

A high throughput assay measuring accumulation of the ABCG2 specific substrate pheophorbide a (PhA) in ABCG2-overexpressing NCI-H460 MX20 cells was developed⁴ and used to screen extracts from the National Cancer Institute's natural products repository. Three of the thirty-five extracts that showed activity in the assay were from the marine crinoids *Capillaster multiradiatus*, *Comanthus parvicirrus* and an unidentified crinoid of the family Comasteridae.⁵ While there are no reports in the literature describing chemical

constituents of the sea star *Capillaster multiradiatus*, *Comanthus parvicirrus* has been known to produce naphthopyrone compounds.⁶ Bioassay-guided fractionation of the three active extracts led to the isolation of five new naphthopyrones (**1-5**) along with the known compounds TMC-256A1 (**6**),⁷ 5,8-dihydroxy-6-methoxy-2-propyl-4*H*-naphtho[2,3-*b*]pyran-4-one (**7**),⁸ TMC-256C1 (**8**),⁷ comaparvin (**9**),⁹ 6-methoxycomarparvin (**10**),⁶ and 6-methoxycomarparvin 5-methyl ether (**11**).⁶ The known compounds were identified by analysis of their spectroscopic data along with comparisons to literature values.

Each crinoid sample was sequentially extracted with 1:1 CH₂Cl₂-MeOH and 100% MeOH to provide the organic solvent extracts. A 2.1 g aliquot of the extract from the as yet taxonomically undefined crinoid was subjected to a solvent-solvent partitioning scheme that concentrated the ABCG2 inhibitory activity into the EtOAc and MeOtBu soluble fractions. The EtOAc fraction was chromatographed on Sephadex LH-20 with 2.5:1 hexane-CH₂Cl₂-MeOH and the active fractions were subjected to C₁₈ reversed-phase HPLC eluting with a linear gradient from 75:25 MeOH/H₂O to 100% MeOH, to yield compounds **1** (1.8 mg), **2** (3.2 mg), **3** (2.0 mg), **4** (5.6 mg), **5** (5.8 mg), **8** (2.6 mg), **9** (2.2 mg), and **10** (5.3 mg). The MeOtBu fraction was chromatographed on Sephadex LH-20 with 1:1 CH₂Cl₂-MeOH and further purified by HPLC as described above to yield compound **11** (1.1 mg).

1 gram of the crude organic extract of *Comanthus parvicirrus* was subjected to the same partitioning scheme as above with the active EtOAc fraction yielding an additional 5 mg of compound **3**. The MeOtBu fraction was chromatographed on Sephadex LH-20 with 1:1 CH₂Cl₂-MeOH, followed by hexane-CH₂Cl₂-MeOH 2.5:1 to give compounds **8** (12 mg) and **9** (40 mg).

A 1 g aliquot of the extract from *Capillaster multiradiatus* was also subjected to a solvent-solvent partitioning scheme that concentrated the ABCG2 inhibitory activity into the EtOAc soluble fraction. This fraction was chromatographed on Sephadex LH-20 with 1:1 CH₂Cl₂-MeOH. Final purification by C₁₈ reversed-phase HPLC as above provided compounds **6** (1.0 mg) and **7** (2.1 mg).

HRFABMS of compound **1**¹⁰ showed a peak at *m/z* 303.0895 [M + H]⁺ indicative of a molecular formula of C₁₆H₁₄O₆ and consistent with 10 double bond equivalents. The ¹³C NMR (Table 1) and HSQC spectra showed 16 carbon signals including one methyl, two methoxyl groups, three *sp*² methines, and ten quaternary *sp*² carbons, one of which was a carbonyl. The ¹H NMR spectrum showed signals for one singlet methyl (δ 2.41), two methoxyls (δ 3.84, 3.85), one singlet aromatic proton (δ 6.14), two *meta*-coupled aromatic protons (δ 6.45, 6.87, *J* = 2.0 Hz), and two phenolic hydroxyl protons (δ 10.41, 14.56), one of which was intramolecularly hydrogen-bonded. The NMR spectra of **1** were very similar to those of compound **6** which was identified as the known naphthopyrone TMC-256A1 by comparison with literature values.⁷

The difference in the NMR spectra between **1** and **6** was the observation of ¹³C and ¹H resonances (δ 60.6 and δ 3.84) in **1** which were consistent with an additional methoxyl substituent. Analysis of the HMBC spectrum of **1** established the location of the hydroxyl and methoxyl groups. An HMBC correlation from the hydroxyl proton at δ 14.56 to C-4a (δ 102.2), C-5 (δ 157.9) and C-5a (δ 106.5), along with the sharp ¹H signal, established that a hydroxyl group was substituted at C-5 and that it was hydrogen-bonded to a nearby carbonyl. A methoxyl group at δ 3.85 was positioned on C-8 by HMBC correlations to C-8 (δ 161.1) and a four-bond correlation to C-7 (δ 97.7). An HMBC correlation from δ 3.84 to C-10 (δ 130.2) placed the remaining methoxyl group on C-10. A NOE interaction between the protons at δ 14.56 and δ 10.41 placed the remaining hydroxyl group on C-6 (δ 160.3).

The molecular formula of compound **2**¹¹ was established as C₁₈H₁₈O₆ by HRFABMS (*m/z* 331.1174 [M + H]⁺). The NMR and UV spectra were very similar to the naphthopyrone core of compound **1** and additional ¹³C (δ 13.3 and δ 19.6) and ¹H methylene resonances (δ 0.98 and δ 1.73) were attributed to a propyl substitution on C-2 (δ 170.9). This was supported by an HMBC correlation from H-3 (δ 6.13) to the methylene carbon at δ 35.2, and from the methylene proton at δ 2.66 to C-2 (δ 170.9) and C-3 (δ 106.1).

Compound **3**¹² had the same molecular formula of C₁₆H₁₄O₆ (*m/z* 303.0868 [M + H]⁺) as compound **1** by HRFABMS but differed in the UV, ¹³C and ¹H spectra. UV differences between linear and angular naphthopyrones are well documented¹³ and absorptions at 245, 285 and 370 nm for **3** indicated an angular naphthopyrone. This was also shown by the upfield shift of the C-5 OH proton signal at δ 13.08 compared to δ 14.56 for the linear naphthopyrone **1**. The hydroxyl group was positioned on C-5 by HMBC correlations to C-5 (δ 145.8) and C-4a (δ 107.6), and an HMBC correlation between the methoxyl resonance at δ 3.84 to C-6 (δ 133.5) established the presence of a methoxyl group at C-6. A literature search allowed us to determine that **3** differed from the known compound **10** by the substitution of a methyl group on C-2 (δ 167.5).⁶

The molecular formula for compound **4**¹⁴ was established as C₁₇H₁₆O₆ by a HRFABMS measurement of *m/z* 317.1092 [M + H]⁺ which differed from **3** by the addition of 14 Da. The NMR and UV data for **4** corresponded closely to those of **3** except for the loss of a signal at δ 13.08 characteristic of a hydroxyl proton and the appearance of an additional methoxyl (δ 3.77 and δ 61.4). An HMBC correlation between the methoxyl resonance at δ 3.77 to C-5 (δ 146.0) established the presence of the methoxyl group at this position.

Compound **5**¹⁵ also showed characteristic UV signals at 240, 275 and 360 nm indicative of an angular naphthopyrone and had NMR data similar to **9**. HRFABMS measurement of a peak corresponding to MH⁺ (*m/z* 315.1199) established a molecular formula of C₁₈H₁₈O₅ for compound **5**. This differed from the known compound **9** by the addition of 14 Da. An HMBC correlation from an additional methoxyl group (δ 3.83 and δ 55.6) to C-5 (δ 155.8) showed the replacement of a hydroxyl group at this position and accounted for the 14 amu difference.

A high throughput assay measuring accumulation of the ABCG2 substrate PhA in ABCG2-overexpressing NCIH460 MX20 cells was used for bioassay-guided isolation of the compounds.⁴ The known inhibitor, fumitremorgin C (FTC, 1 μM) was used as a positive control and data were normalized to FTC and reported as the percentage of FTC induced fluorescence (Table 2).

Although none of the linear naphthopyrones tested inhibited ABCG2-mediated transport, inhibition of Pgp-mediated drug efflux by linear naphthopyrones has been previously reported.¹⁶ Of the seven angular naphthopyrones tested, six showed weak to moderate activity varying from 27% to 59% of that obtained with the positive control, FTC. Compound **4** did not show activity even though it only differs from **11** by the substitution of a methyl instead of propyl group on C-2. This loss of activity due to a minor substitution was also observed in the botryllamide class of compounds.³ Although the naphthopyrones did not show strong inhibition of ABCG2-mediated transport they reinforced the emerging role of natural products in the development of inhibitors/modulators of multidrug resistance.

Acknowledgments

This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E and has been supported in part by the Intramural Research Program of NIH, National Cancer Institute, Center for Cancer Research. The content of this publication

does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. We thank G. Cragg (NPB) for the contract collection, and T. McCloud for extractions.

References and Notes

1. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. *J. Natl. Cancer Inst* 2000;92:1651. [PubMed: 11036110]
2. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. *Cancer Res* 2001;61:3458. [PubMed: 11309308]
3. Henrich CJ, Robey RW, Takada K, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, McMahon JB, Gustafson KR. *ACS Chem. Biol* 2009;4:637. [PubMed: 19555120]
4. Henrich CJ, Bokesch HR, Dean M, Bates SE, Robey RW, Goncharova EI, Wilson JA, McMahon JB. *J. Biomol. Screen* 2006;11:176. [PubMed: 16490770]
5. *Capillaster multiradiatus* was collected in Palau (1993) by P. Collin of the Coral Reef Research Foundation. *Comanthus parvicirrus* and a taxonomically unidentified crinoid were collected in northern Australia (1991 and 1988, respectively) by P. Murphy of the Australian Institute of Marine Sciences. Voucher specimens (*Capillaster* - 0CDN1152, *Comanthus* - Q66C5685, unknown - Q66C1600) are maintained at the Smithsonian Institute.
6. Folmer F, Harrison WT, Tabudravu JN, Jaspars M, Aalbersberg W, Feussner K, Wright AD, Dicato M, Diederich M. *J. Nat. Prod* 2008;71:106. [PubMed: 18088098]
7. Sakurai M, Kohno J, Yamamoto K, Okuda T, Nishio M, Kawano K, Ohnuki T. *J. Antibiot. (Tokyo)* 2002;55:685. [PubMed: 12374380]
8. Francesconi KA. *Aust. J. Chem* 1980;33:2781.
9. Smith IR, Sutherland MD. *Aust. J. Chem* 1971;24:1287.
10. (1): $[\alpha]_D^{25} -36.6$ (*c* 0.18, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 220 (3.95), 280 (4.38), 415 (3.58) nm; ^1H and ^{13}C NMR data, see Table 1; HRFABMS m/z 303.0895 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{16}\text{H}_{15}\text{O}_6$, 303.0869).
11. (2): $[\alpha]_D^{25} -32.9$ (*c* 0.04, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 224 (4.32), 280 (4.38), 415 (3.58) nm; ^1H and ^{13}C NMR data, see Table 1; HRFABMS m/z 331.1174 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{18}\text{H}_{19}\text{O}_6$, 331.1182).
12. (3): $[\alpha]_D^{25} -7.88$ (*c* 0.29, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 245 (4.04), 285 (3.81), 370 (3.21) nm; ^1H and ^{13}C NMR data, see Table 1; HRFABMS m/z 303.0868 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{16}\text{H}_{15}\text{O}_6$, 303.0869).
13. Priestap HA. *Tetrahedron* 1984;40:3617.
14. (4): $[\alpha]_D^{25} -62.0$ (*c* 0.20, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 234 (4.23), 275 (4.15), 365 (3.68) nm; ^1H and ^{13}C NMR data, see Table 1; HRFABMS m/z 317.1092 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{17}\text{H}_{17}\text{O}_6$, 317.1026).
15. (5): $[\alpha]_D^{25} -16.8$ (*c* 0.08, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 240 (4.78), 275 (4.63), 360 (4.04) nm; ^1H and ^{13}C NMR data, see Table 1; HRFABMS m/z 315.1199 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{18}\text{H}_{19}\text{O}_5$, 315.1232).
16. Ikeda S, Sugita M, Yoshimura A, Sumizawa T, Douzono H, Nagata Y, Akiyama S. *Int. J. Cancer* 1990;45:508. [PubMed: 1968438]

Table 1

¹H (500 MHz) and ¹³C (125 MHz) NMR Spectral Data for Compounds 1-5 (DMSO-*d*₆, δ in ppm)

Position	1		2		3		4		5	
	¹³ C δ	¹ H δ, (mult, J Hz)	¹³ C δ	¹ H δ, (mult, J Hz)	¹³ C δ	¹ H δ, (mult, J Hz)	¹³ C δ	¹ H δ, (mult, J Hz)	¹³ C δ	¹ H δ, (mult, J Hz)
2	168.2		170.9		167.5		163.1		165.5	
3	106.5	6.14, s	106.1	6.13, s	109.2	6.42, s	111.6	6.15, s	112.0	6.11, s
4	183.7		183.7		182.5		175.7		175.7	
4a	102.2		102.4		107.6		113.3		110.9	
5	157.9		157.9		145.8		146.0		155.8	
5a	106.5		106.5							
6	160.3		160.3		133.5		142.6		101.5	6.90, s
6a					135.4		134.2		139.4	
7	97.7	6.45 (d, 2.0)	97.7	6.44 (d, 2.0)	95.3	6.91 (d, 1.5)	96.3	6.97 (d, 2.0)	101.5	6.68 (d, 2.0)
8	161.1		161.1		160.2		159.7		159.4	
9	94.9	6.87 (d, 2.0)	94.9	6.87 (d, 2.0)	97.6	6.52 (d, 1.5)	99.6	6.63 (d, 2.0)	97.8	6.48 (d, 2.0)
9a	135.4		135.4							
10	130.2		130.3		159.5		159.3		158.8	
10a	143.4		143.4		103.1		106.6		104.2	
10b					151.5		152.7		156.8	
2-CH ₃	20.2	2.41	35.2	2.66 (t, 7.5)	20.0	2.48, s	19.2	2.36, s	13.3	0.95 (t, 7.5)
2-CH ₂			19.6	1.73 (hex, 7.5)					19.0	1.78 (hex, 7.5)
2-CH ₂			13.3	0.98 (t, 7.5)					34.6	2.60 (t, 7.5)
5-OH	14.56			14.55, s		13.08				
6-OH	10.41			10.39, s						
8-OH						10.4		10.30, s		10.20, s
5-OCH ₃							61.4	3.77, s	55.6	3.83, s
6-OCH ₃					59.5	3.84, s	60.8	3.85, s		
8-OCH ₃	55.8	3.85	55.8	3.85, s						
10-OCH ₃	60.6	3.84	60.7	3.84, s	56.1	3.94, s	56.2	3.92, s	55.9	3.90, s

Table 2Effects of naphthopyrones (**1** – **11**) on PhA accumulation

Compounds	Maximum activity, % FTC ^a	IC ₅₀ , μ M ^b
3	59.3 ($\pm$ 1.4)	11.9 ($\pm$ 1.8)
5	46.3 ($\pm$ 1.2)	5.9 ($\pm$ 0.5)
8	31.0 ($\pm$ 1.0)	12.8 ($\pm$ 0.4)
9	54.3 ($\pm$ 2.3)	9.0 ($\pm$ 0.8)
10	27.5 ($\pm$ 3.5)	>20 ^c
11	44.0 ($\pm$ 8.0)	16.6 ($\pm$ 4.1)
1, 2, 4, 6, 7	na	na

^a Maximal activities and IC₅₀ values for inhibition of PhA accumulation were determined from dose-response curves (na = not active).

^b Apparent IC₅₀ values were calculated from dose-response data using SigmaPlot (SPSS, Inc., Chicago) 4-parameter logistic nonlinear regression analysis. Values shown are average $\pm$ SEM (3 plates, duplicate wells per plate).

^c Highest concentration tested.